Travelling to Basel, Switzerland for Informa Connect / EBD Group’s BIO-Europe Spring, taking place at the Messe Congress Center between the 20th and 22nd March, pharmaphorum listened to par
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh